News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Subscribe To Our Newsletter & Stay Updated
